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Despite significant heritability of autism spectrum
disorders (ASDs), their extreme genetic heteroge-
neity has proven challenging for gene discovery.
Studies of primarily simplex families have implicatedde novo copy number changes and point mutations,
but are not optimally designed to identify inherited
risk alleles. We apply whole-exome sequencing
(WES) to ASD families enriched for inherited causes
due toconsanguinity andfind familial ASDassociatedNeuron 77, 259–273, January 23, 2013 ª2013 Elsevier Inc. 259
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Inherited Causes of Autismwith biallelicmutations in disease genes (AMT,PEX7,
SYNE1,VPS13B,PAH, andPOMGNT1). At least some
of these genes show biallelic mutations in noncon-
sanguineous families as well. These mutations are
often only partially disabling or present atypically,
with patients lacking diagnostic features of the
Mendelian disorders with which these genes are
classically associated. Our study shows the utility of
WES for identifying specific genetic conditions not
clinically suspected and the importance of partial
loss of gene function in ASDs.
INTRODUCTION
Despite studies suggesting that autism spectrum disorders
(ASDs) are significantly heritable, the basis of this heritability
remains largely unexplained (Devlin and Scherer, 2012). Autism
is characterized by the triad of communication deficits, abnor-
mal social interests, and restricted and repetitive behaviors.
Genome-wide association studies (GWAS) have so far detected
no strong contribution of common alleles (State, 2010), moti-
vating renewed interest in rare variants (Malhotra and Sebat,
2012). Transmitted, rare copy number variants (CNVs), such as
16p11.2 microdeletion/duplication and 15q11.2–q13 duplication
have been found to contribute, although the total number of
cases accounted for by these conditions is small (Levy et al.,
2011; Pinto et al., 2010; Weiss et al., 2008). Significant roles
have also been demonstrated for diverse, de novo CNVs (Levy
et al., 2011; Sanders et al., 2011; Sebat et al., 2007) and more
recently, de novo, protein-altering point mutations (Iossifov
et al., 2012; Neale et al., 2012; O’Roak et al., 2011; O’Roak
et al., 2012; Sanders et al., 2012). In the cohorts examined, de
novo events may be projected to account for up to 15%–20%
of ASD cases. Despite the high total rate of de novo point muta-
tions, estimates of the number of contributing loci to autism
susceptibility are in the several hundreds, so that validating
specific causative genes is a significant challenge, since recur-
rent mutation in any given gene is so uncommon. Nonethe-
less, these studies have been successful at elucidating gene
dosage-sensitive ASD molecular pathways, since the typical
mutations observed are loss/disruption, or sometimes gain, of
one functional copy of a gene or contiguous genes, rather than
biallelic mutations of both copies of a gene. However, despite
the importance of de novo mutations, much of the heritability
of ASDs remains unaccounted for (Devlin and Scherer, 2012).
We hypothesized that at least some cases of autism reflect
rare, inherited point mutations that existing study designs, often
involving families with one or two affected individuals, are not
designed to capture. Consanguineous and multiplex pedigrees
have been extremely useful for identifying inherited mutations
responsible for rare heritable conditions in the setting of extreme
genetic heterogeneity, because single families can provide sub-
stantial genetic linkage evidence (Lander and Botstein, 1987;
Woods et al., 2006). Applying high-throughput sequencing to
such families has been extremely useful in identifying recessive
causes of intellectual disability (Najmabadi et al., 2011). The260 Neuron 77, 259–273, January 23, 2013 ª2013 Elsevier Inc.potential role of biallelic mutations in ASDs is strongly supported
by a number of syndromic recessive conditions that have
already been associated with autistic symptoms (Betancur,
2011). Additional evidence supporting a role of biallelic muta-
tions comes from studies that have implicated homozygous
CNVs (Levy et al., 2011; Morrow et al., 2008) and long homozy-
gous intervals as significantly associated with ASDs (Casey
et al., 2012). Finally, a recent whole-exome sequencing (WES)
study has suggested a role for biallelic point mutations in
a subset of patients with ASDs that show long runs of homozy-
gosity (Chahrour et al., 2012).
In this study, we apply WES to a cohort of consanguineous
and/or multiplex families with ASD that also show shared
ancestry between the parents, typically as cousins. We find
several families where mapping and sequence analysis allow
the identification of specific causative mutations and show that
many of these mutations represent partial loss of function in
genes where null mutations cause distinctive Mendelian disor-
ders. These hypomorphic mutations confirm the complex and
heterogeneous nature of ASDs, but also highlight the importance
of WES in identifying specific genetic causes underlying this
heterogeneity.
RESULTS
Identifying Inherited Mutations in Three ASD Families
We studied an ASD cohort recruited by the Homozygosity
Mapping Collaborative for Autism (HMCA), an international,
multicenter effort to identify genetically informative ASD families
with consanguinity and/or multiple affected individuals (Morrow
et al., 2008). We first performed genome-wide linkage analysis
on the most informative families, using high-resolution single
nucleotide polymorphism (SNP) arrays, reasoning that some
families would show homozygous, biallelic mutations embedded
within larger blocks of homozygosity inherited from the ancestor
common to both parents. Families were prescreened to exclude
those harboring autism-associated CNVs or other known diag-
noses (Supplemental Experimental Procedures). Three families
provided particularly strong genetic power to localize potential
disease loci.
The first family had three children affected with ASD and
two unaffected children, born to parents who were first cousins
(Figure 1A; Table 1B; see Supplemental Text available online).
Mapping under a single locus, biallelic model (i.e., allowing for
both homozygous and compound heterozygous mutations) ex-
cluded 99.3% of the genome and revealed a single linkage
peak centered at 3p21.31, in a large homozygous interval, reach-
ing the maximum LOD score obtainable in the pedigree, 2.96
(Figure 1B), suggesting a >900:1 likelihood that the responsible
mutation was contained within this homozygous interval. WES
of a single affected child was performed. The linked interval
contained only a single rare, nonsynonymous change that was
absent from known databases and population-matched con-
trols: a homozygous single base substitution in the aminomethyl-
transferase (AMT) gene, encoding an enzyme essential for the
degradation of glycine. The mutation resulted in p.I308F, altering
an Ile residue that is highly conserved in all AMT orthologs
(Figure 1C) and is packed tightly into a hydrophobic pocket
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confirmed that the mutation was heterozygous in both parents,
homozygous in all affected children, and absent or heterozygous
in the two unaffected children.
Mutations in AMT classically cause nonketotic hyperglycine-
mia (NKH) (Applegarth and Toone, 2004), a neonatal syndrome
leading to progressive lethargy, hypotonia, severe seizures,
and death within the first year of life (Hamosh and Johnston,
2001). Patients with neonatal NKH have impaired activity of the
glycine cleavage system, leading to abnormal elevation of
glycine levels in serum or cerebrospinal fluid (CSF). Rarer, atyp-
ical forms of NKH have been described in association with hypo-
morphic, missense AMT mutations (Applegarth and Toone,
2001; Dinopoulos et al., 2005), manifesting as later age of clinical
onset, delays in expressive language, behavioral problems, and
variable or absent seizures. Clinical and biochemical evidence
suggests that the p.I308F mutation is hypomorphic. While
individually nondiagnostic, the three affected children in this
family exhibited a range of neurologic symptoms that in aggre-
gate were strongly suggestive of NKH (Supplemental Text).
The eldest child was twelve years old and had, in addition to
a diagnosis of ASD, a history of severe epilepsy, with first
seizures presenting by age 10 months, very consistent with
NKH. The second child was nine years old and also suffered
from a combination of autism and epilepsy, though her seizures
were milder. The third child was two years old, suffered from
language and motor delays, and carried a presumptive PDD
diagnosis. He had had only a single febrile seizure. Though the
two older children had had plasma amino acid screening that
disclosed no abnormalities, milder forms of NKH typically have
no abnormalities on serum biochemical analyses (Applegarth
and Toone, 2001; Dinopoulos et al., 2005).
Direct biochemical analysis of the p.I308F mutation confirms
that it has reduced activity. While wild-type AMT is fully soluble
at 30C when expressed in bacteria, mutant AMT p.I308F was
very poorly soluble (Figure 1E), indicating a protein folding
defect, similar to that observed with NKH-associated AMTmuta-
tions (Figure S1; Table S1). This defect could be rescued by co-
expressing GroES and GroEL heat-shock proteins at 22C (Fig-
ure 1E). AMT p.I308F, even after solubilization, retained only
45% (SD 4.1%) and 1.8% (SD 0.5%) of wild-type glycine
cleavage and glycine synthesis specific activity, respectively,
when assayed enzymatically (Figures 1F and S2). When com-
pared to classical NKH-associated alleles, glycine cleavage
activity of AMT p.I308F is at the mild end of the range of previ-
ously reported values (Figures 1F and S2), further suggesting
that the affected autistic children in this family suffer from undi-
agnosed, atypical NKH presenting as ASD and seizures.
A secondconsanguineous family had three children diagnosed
with ASD and three unaffected children, born to unaffected
parents who were first cousins (Figure 2A; Table 1B; Supple-
mental Text). Parametric mapping excluded 97.2% of the
genome and established linkage to a homozygous interval on
6p23 (Figure 2B) (LOD 2.78, themaximum obtainable in the pedi-
gree, under a recessivemodel, indicating a >600:1 likelihood that
this interval contained the disease-causingmutation). WES iden-
tified only one variant, absent from known databases and popu-
lation-matched controls, in this region that was predicted to bepathogenic: PEX7 p.W75C. This change was homozygous and
altered a highly conserved Trp residue within a WD-40 repeat
of the predicted protein (Figures 2C and 2D). Sanger validation
confirmed that this mutation was heterozygous in both parents,
and heterozygous or wild-type in unaffected children.
PEX7 encodes a receptor required for import of PTS2 (peroxi-
some targeting signal 2)-containing proteins into the peroxi-
some (Braverman et al., 1997). Null mutations in PEX7 cause
rhizomelic chondrodysplasia punctata (RCDP), an inborn meta-
bolic syndrome of abnormal facies, cataracts, skeletal dysplasia,
epilepsy, and severe psychomotor defects, with most cases not
surviving beyond two years of age (Braverman et al., 2002; Brav-
erman et al., 1997; Motley et al., 1997). The affected children in
this family, however, ranged in age from 18 to 31 years. They
were not dysmorphic and did not exhibit skeletal dysplasia,
though two had cataracts and two had epilepsy (Supplemental
Text). The cataracts and seizures in particular suggested partial
loss of PEX7 function, since rare, atypical RCDP cases associ-
ated with hypomorphic compound heterozygous or homozy-
gous mutations have been described that have some but not
all of the features of the classical syndrome, lacking dysmorphic
features and showing only intellectual disability with variable
cataracts (Braverman et al., 2002).
To evaluate whether the p.W75C missense change in this
family could be pathogenic, we assayed its ability to rescue
peroxisomal import in cultured fibroblasts from a RCDP patient.
In RCDP fibroblasts, fluorescent mCherry fused to the PTS2
peroxisomal targeting sequence fails to be imported into perox-
isomes and remains cytosolic (Figure 2E). Cotransfection of wild-
type PEX7 fully restores peroxisomal import (Figure 2E). In
contrast, transfection with PEX7 p.W75C failed to rescue (Fig-
ure 2E): the majority of cells showed cytosolic PTS2-mCherry,
although a fraction showed partial rescue. To characterize this
effect, we utilized a semiquantitative assay of peroxisomal
import. The PTS2 proteins thiolase, phytanoyl-CoA hydroxylase
(PhyH), and alkylglycerone phosphate synthase (AGPS) are
imported into the peroxisome and proteolytically processed
into smaller, mature forms (Figure 2F). Peroxisomal uptake is
thus reflected in the ratio of the mature protein to the preprotein.
In RCDP cells, these three proteins all remain in the preprotein
state, reflecting failure of peroxisomal import. Transfection of
wild-type PEX7 fully restores processing, whereas transfection
of PEX7 p.W75C produced only partial processing (Figure 2F).
These results demonstrate that this allele is pathogenic, but
partial loss of function, consistent with these individuals not
exhibiting full features of the RCDP syndrome.
To our knowledge, a link between mild RCDP and ASDs has
not been described previously. However, two previously re-
ported patients with biochemical evidence of RCDP and cata-
racts, but lacking the dysmorphic features of RCDP, were found
to be compound heterozygous for partial loss-of-function PEX7
mutations (Braverman et al., 2002); one was originally described
as intellectually disabled and the second as neurotypical. We
recontacted these patients. A review of clinical records and reex-
amination of the first child revealed that she had subsequently
been diagnosed with ASD, and the second child was diagnosed
with severe ADHD, providing additional examples of the range of
clinical expressivity of mild mutations in PEX7. Partial loss ofNeuron 77, 259–273, January 23, 2013 ª2013 Elsevier Inc. 261
Figure 1. Identification of Mutations in AMT in a Family with ASD
(A) AU-1700, a Saudi family with three children affected by autism. Shaded symbols indicate affected individuals. The triangle represents a miscarriage. WES
was performed on samples from individuals indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where
indicated (+, reference allele; , alternate allele).
(B) Mapping to a locus on chromosome 3. Genome-wide linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).
(legend continued on next page)
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Inherited Causes of Autismfunction for one of the alleles in these patients, S25F, was verified
in fibroblast assays (Figures 2E and 2F).
Analysis of a third large family pointed to a candidate autism
gene potentially implicated in synaptic plasticity, SYNE1. In
this family, five children were born to parents who were double
first cousins. Four were affected with autism and the fifth child
was unaffected (Figure 3A; Supplemental Text). The family
showed linkage to two loci on chromosome 6q25 and 7q33
(LOD 2.83, maximal obtainable in the pedigree, indicating a
>670:1 chance that the disease-causing gene lies in one of
these intervals) (Figure 3B). WES was performed for the entire
nuclear family. No rare, protein-altering variants were found in
the 7q33 linkage interval, whereas 6q25 harbored only one
protein-altering variant, absent from known databases and
population-matched controls, that segregated with disease: a
homozygous missense change in SYNE1 (p.L3206M) (Table 1).
SYNE1 has previously been implicated as an ASD gene candi-
date by the presence of a de novo single nucleotide variant in
a patient with ASD (O’Roak et al., 2011) and has been implicated
in bipolar disorder in aGWAS study (Sklar et al., 2011; Figure 3C).
Truncating, presumably null, mutations in SYNE1 cause cere-
bellar ataxia (Gros-Louis et al., 2007) and a recessive form of
arthrogryposis multiplex congenita (Attali et al., 2009; Figure 3C),
again suggesting that the ASD-associated allele may be hypo-
morphic, since the phenotype is milder. SYNE1 p.L3206M alters
a highly conserved residue that lies within a spectrin repeat (Fig-
ure 3D; SIFT score 0.01).
Full-length SYNE1 encodes a large 8,797 amino acid protein
with two N-terminal actin-binding domains, multiple spectrin
repeats, a transmembrane domain, and a C-terminal KASH
domain. The SYNE1 mutation identified here is predicted
to map to exon 61 of the full-length transcript (RefSeq NM_
182961), although the SYNE1 locus is complex, with many pre-
dicted alternative splice forms (Simpson and Roberts, 2008).
To identify what human transcript(s) might be affected by the
p.L3206M mutation, we mapped transcriptional start sites in
human neurons using ChIPseq (Figure 3E). ChIPseq using anti-
bodies to H3K4Me3, a mark associated with active promoter
sites (Ernst et al., 2011), and to H3K27Ac, a mark associated
with enhancer elements (Heintzman et al., 2009), demonstrated
mapped read peaks corresponding to at least four major tran-
scriptional start sites within the SYNE1 locus (P1–P4), one of
which (P3) lies immediately upstream of the p.L3206M mutation
(Figure 3E). 50 and 30 RACE (data not shown) confirmed the
existence of at least one polyadenylated transcript emanating(C) Ile308 residue is highly conserved across species.
(D) Mapping of the I308F missense mutation onto the human AMT crystal structu
(Right) Detail illustrating the hydrophobic pocket in which I308 resides. Neighbor
different domains: AMT domain 1 (folding); AMT domain 2 (catalytic); AMT doma
(E) I308F results in protein misfolding and aggregation. C-terminal 6xHis-tagged h
overexpressed at 30C by induction with 25 mM IPTG, wild-type AMTwas fully sol
expression levels. W, whole-cell extract; S, supernatant; P, pellet. Right panel, slo
type solubility could be achieved by coexpression with GroEL and GroES.
(F) AMT I308F results in partial loss-of-function of glycine cleavage and synthesi
purified, and assayed for glycine cleavage and glycine synthesis activity. Relativ
reduction of activity in glycine cleavage (left) and glycine synthesis (right) assay
(Okamura-Ikeda et al., 2005).
See also Figures S1, S2, and S5 and Table S1.from this promoter, corresponding to GenBank mRNA clone
BC039121, encompassing exons 57–63 of the predicted full-
length SYNE1 mRNA. This is the minimal confirmed transcript
that overlaps the p.L3206M mutation, although contributions of
additional or even full-length transcripts cannot be excluded.
SYNE1 has been shown to have roles in cellular nuclear migra-
tion in C. elegans and Drosophila (Starr and Han, 2002; Zhang
et al., 2002), anchoring of synaptic nuclei with postsynaptic
membranes at the vertebrate neuromuscular junction (Grady
et al., 2005), although based upon patients with SYNE1-associ-
ated cerebellar ataxia, it has been suggested that vertebrates
may have compensatory mechanisms for these two processes
and that SYNE1 may have adapted to perform a specialized
function in the brain (Gros-Louis et al., 2007). In rodents, a spec-
trin-rich splice form of SYNE1 called CPG2 has been shown to
control dendritic spine shape and glutamate receptor turnover
in response to neuronal activity (Cottrell et al., 2004). To test
whetherSYNE1might be responsive to neuronal activity, we per-
formed RNaseq on cultured human primary neurons, before and
after depolarization. Transcription of full-length SYNE1 was in-
duced 1.27-fold (n = 5, SE 0.06, p = 0.0203, t test, one-tailed)
by neuronal activity, and transcription of BC039121 was induced
by 1.50-fold (n = 5, SE 0.11, p = 0.0225, t test, one-tailed) across
five biological replicates (Figures 3E and S2). This suggests that
both full-length SYNE1 and the shorter BC039121 isoform may
have neuronal activity-dependent roles in regulating synaptic
strength, like other synaptic genes implicated in autism.
WES for Known Disease Genes
Our findings of inherited, biallelic, hypomorphic ASD mutations
in larger families prompted us to ask whether additional cases
of ASD might be explained by either unsuspected or atypical
presentations of known diseases. Over 450 genes have been
identified that, when mutated, have neurocognitive impact (van
Bokhoven, 2011). To increase the specificity of our analysis,
we chose to analyze a limited subset of 70 of these genes,
each associated with a monogenic, autosomal recessive or
X-linked neurodevelopmental syndrome in which autistic fea-
tures have been previously described (Table S2; Betancur,
2011). We also screened for additional alleles of AMT, PEX7,
and SYNE1. We used WES to screen for mutations in these
genes in a total of 163 consanguineous and/or multiplex families
using established heuristic filtering for rare, high penetrance
disease (Bamshad et al., 2011; Stitziel et al., 2011) to identify
homozygous, compound heterozygous, or hemizygous variantsre (PDB accession 1WSV). (Left) Overview showing I308 in domain 3 of AMT.
ing hydrophobic residues are shown in white. The white brackets indicate the
in 3 (capping).
uman AMT, AMT I308F, and AMT I308A were expressed in E. coli. (Left) When
uble, but I308F and I308A segregated to inclusion bodies despite overall similar
wer induction at 22C for 44 hr resulted in partially soluble mutants. Near-wild-
s activity. Wild-type and mutant 6xHis-human AMT were expressed in E. coli,
e to wild-type (blue traces), AMT I308F (red traces) demonstrates significant
s. R320H, N145I, and G269D are previously reported NKH-associated alleles
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Table 1. Inherited Mutations Identified in ASDs
(A) Severe Mutations
Mutation Known Disease Association Family Structure Consanguinity # Affected # Unaffected Linkage Primary
Phenotype
Additional Phenotypes
MECP2 p.E483X Rett syndrome, ASD AU-5400 Multiplex No 2 (2M) — Yes Autism —
NLGN4X p.Q329X Nonsyndromic X-linked ID and/or ASD AU-5700 Simplex Yes 1 (M) 1 Yes Autism —
PAH p.198_205 del Phenylketonuria AU-13100 Simplex Yes 1 (M) 2 Yes Autism ID
PAH p.Q235X Phenylketonuria AU-4100 Multiplex Yes 2 (2F) — Yes Autism —
VPS13B p.A3943fs Cohen syndrome AU-21100 Simplex Yes 1 (M) 3 Yes Autism ID, dysmorphic features,
hyperextensible joints
(B) Hypomorphic Mutations
Mutation Known Disease Association Family Structure Consanguinity #Affected # Unaffected Linkage Primary
Phenotype
Additional Phenotypes
AMT p.I308F Nonketotic hyperglycinemia AU-1700 Multiplex Yes 3 (2M, 1F) 2 Yes Autism ID, seizures
AMT p.D198G Nonketotic hyperglycinemia AU-11800 Simplex Yes 1 (M) 1 Yes Autism ID, seizures
PEX7 p.W75C Rhizomelic chondrodysplasia punctata AU-3500 Multiplex Yes 3 (2M, 1F) 3 Yes PDD-NOS ID, seizures, cataracts
POMGNT1 p.R367H Muscle–eye–brain disease AU-13300 Simplex Yes 1 (M) 1 Yes Autism ID
SYNE1 p.L3206M Autosomal recessive cerebellar ataxia type 1,
arthrogryposis congenita, ASD, bipolar disease
AU-1600 Multiplex Yes 4 (1M, 3F) 1 Yes Autism ID
VPS13B p.S824A Cohen syndrome AU-17800 Simplex Yes 1 (M) 1 Yes Autism ID, dysmorphic features,
hyperextensible joints
Severe (nonsense, frameshift) (A) and hypomorphic (missense) (B) mutations in known disease genes were identified in 11 ASD families. M, male; F, female; ID, intellectual disability. See also
Tables S3 and S4.
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Inherited Causes of Autismwith allele frequencies of less than 1% (dbSNP132, 1000
Genomes Project, NHLBI Exome Sequencing Project, and
population-matched controls consisting of 831 exomes from
the Middle Eastern population; see Experimental Procedures
for details) and which were predicted to be protein altering
(missense, nonsense, splice site, or frameshift). Candidatemuta-
tions were confirmed by Sanger sequencing in the entire family
and were required to segregate with disease status within the
family (i.e., homozygous or hemizygous in the affected individ-
uals, inherited in the heterozygous state from parents, and
heterozygous or absent from unaffected siblings). An overview
of the analytic strategy is shown in Figure 4.
In five families (Tables 1A and S4), our screen revealed molec-
ular genetic diagnoses due to severe loss of function (nonsense
or frameshift) hemizygous or homozygous mutations in known
genes. One of these was a nonsense mutation in NLGN4X
(p.Q329X), found in a single affected male child. NLGN4X is
an X-linked gene encoding a neuronal synaptic adhesion
molecule, and mutations in NLGN4X have been described in
individuals with autism, Asperger syndrome, and intellectual dis-
ability (Jamain et al., 2003). This mutation was inherited from
an unaffected mother, consistent with prior observations that
carrier females may be asymptomatic (Su¨dhof, 2008; Table
1A; Figure S4).
In another family, two male children affected with autism
carried a nonsense mutation in the X-linked gene MECP2
(p.E483X), the gene responsible for Rett syndrome (Table 1A).
Their mutation was also inherited from the unaffected mother,
who was heterozygous (Figure S4). The finding of MECP2
nonsense mutations in this family was unusual since these are
typically lethal in males (Chahrour and Zoghbi, 2007), suggesting
that this allele is likely hypomorphic. Consistent with this idea,
p.E483X is a late truncation predicted to remove only the last
four amino acids of the full-length protein.
Two consanguineous families had homozygous nonsense or
frameshift mutations in PAH (Table 1A; Figure S4), the cause of
phenylketonuria and one of the earliest neurometabolic syn-
dromes described as a cause of ASD (Zecavati and Spence,
2009). These families were confirmed to have phenylketonuria
by clinical laboratory testing.
An additional ASD family implicated a syndrome associated
with dysmorphic features and microcephaly. We found a homo-
zygous frameshift alteration in VPS13B/COH1 in the proband in
a consanguineous family who had ASD and mild dysmorphic
features (Figure 5A; Table 1A). The mutation (p.A3943fs) causes
truncation of the C-terminal 54 amino acids of VPS13B/COH1.
Recessive mutations in VPS13B/COH1 cause Cohen syndrome,
characterized by a constellation of intellectual disability, facial
dysmorphism, retinal dystrophy, truncal obesity, joint laxity,
intermittent neutropenia, and postnatal microcephaly (Hennies
et al., 2004) that has previously been associated with autistic
symptoms in some cases (Douzgou and Petersen, 2011). How-
ever, significant variability in the features associated with Cohen
syndrome makes clinical diagnosis challenging (Mochida et al.,
2004; Seifert et al., 2006). The affected child in our cohort had
several features that suggest a diagnosis of Cohen syndrome,
including microcephaly (head circumference 49 cm at age 9,
3rd percentile) and the characteristic facial dysmorphismstypically seen in Cohen syndrome (Figures 5B and 5C; Supple-
mental Text).
In addition to severe loss-of-function mutations, a significant
proportion of rare missense variants are also expected to be
significantly deleterious (Kryukov et al., 2007), as underscored
by our AMT and PEX7 findings. Eleven families were found to
have rare, segregating, homozygous or hemizygous missense
changes in known genes (Tables 1B, S3, and S4). While some
of thesemay be expected to be functionally silent, we found clin-
ical and/or biochemical evidence supporting their pathogenicity
in at least four instances (Table 1B).
In one consanguineous ASD family, we identified a linked
homozygous missense change in AMT (p.D198G) in a single
affected child with ASD and intellectual disability (Table 1B).
This variant was heterozygous in both parents and an unaffected
sibling, and disrupts a highly conserved residue of AMT
(SIFT score 0.01). Functional assays of AMT p.D198G demon-
strated that, like p.I308F and other NKH-associated mutations,
p.D198G is poorly soluble (Figure S5). AMT p.D198G also ex-
hibited a temperature-sensitive protein stability defect (Fig-
ure S5). Enzyme specific activity was preserved (Figure S5),
suggesting that pathogenicity may be due to protein misfold-
ing/stability and not catalytic dysfunction, similar to what is
observed for p.G47R, a known NKH-associated AMT mutation
(Figure S1; Table S1). These findings suggest that this child
may have also suffered from undiagnosed, atypical NKH.
A child affected with ASD and moderate intellectual disability
was found to have a homozygous missense change (p.R367H)
in POMGNT1 (Table 1B; Figure S4). POMGNT1 is responsible
for an inherited dystroglycanopathy characterized by brain
malformation, intellectual disability, developmental delay, hypo-
tonia, and myopia; interestingly, rare patients have been re-
ported with severe autistic features (Haliloglu et al., 2004; Hehr
et al., 2007). The p.R367H missense variant in this patient
disrupts a highly conserved residue, and this exact allele has
been reported as causative in a patient with relatively mild clin-
ical disease, as a compound heterozygousmutation in combina-
tion with a splice site mutation (Godfrey et al., 2007).
Finally, in another consanguineous family, the single affected
child was homozygous for a rare missense variant (p.S824A) in
VPS13B (Table 1B; Figure S4). The proband had in retrospect
some but not all features of Cohen syndrome (autism with mild
facial dysmorphism and joint laxity), consistent with mild ver-
sions reported previously (Hennies et al., 2004).
To begin to explore how these results might extend to noncon-
sanguineous families, we screened for mutations in genes impli-
cated from our cohort (AMT, PEX7, SYNE1, VPS13B, PAH, and
POMGNT1) in 612 families from the Simons Simplex Collection
(193 trios with parents and affected child, plus 419 quartets
with parents, affected child, and unaffected sibling). An analysis
of publicly released whole-exome sequence data (Iossifov et al.,
2012;O’Roak et al., 2012; Sanders et al., 2012) showed amodest
trend toward an excess of biallelic, inherited, rare (MAF < 1%),
protein-altering variants in cases (8/612) compared to control
siblings (2/419) (p = 0.21, Fisher’s exact test, two-tailed) in at
least one of the genes we screened (Table S5). As expected
for a nonconsanguineous cohort, all but one were found in the
compound heterozygous state. Although functional validationNeuron 77, 259–273, January 23, 2013 ª2013 Elsevier Inc. 265
Figure 2. Identification of Mutations in PEX7 in a Family with ASD
(A) AU-3500, a family with three children affected with ASD. Shaded symbols indicate affected individuals. WES was performed on samples from individuals
indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference allele; –, alternate allele).
(legend continued on next page)
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phenotype data are supportive of the mutations’ pathogenicity.
One affected male child was compound heterozygous for two
different mutations in VPS13B (p.W963X/p.G2704R). Gly2704
is a highly conserved residue, while p.W963X leads to early trun-
cation of the protein and has been previously reported in Cohen
syndrome (Kolehmainen et al., 2004). Review of the clinical
phenotype of this individual confirmed that he manifested,
in addition to autism, features of Cohen syndrome including
prominent microcephaly (<3 SD) and somatic dysmorphisms
(Supplemental Text), making the diagnosis of a Cohen syndrome
mutation highly likely. A second, unrelated male child affected
with autism was compound heterozygous for two rare point
mutations in VPS13B, p.S3303R and p.A3691T, both altering
highly conserved residues. In addition to being autistic, this child
also manifested dysmorphisms of the face and extremities as
well as an abnormal hair growth pattern, known to characterize
Cohen syndrome. These data confirm that biallelic mutations
are also found in nonconsanguineous autism cohorts, but anal-
ysis of much larger numbers of genes and patients will be
needed to quantify their prevalence.
DISCUSSION
Our data combine WES with segregation analysis to demon-
strate that biallelic, hypomorphic mutations underlie at least
a subset of ASDs (Chahrour et al., 2012; Morrow et al., 2008),
and together with a report on biallelic null mutations in this
same issue of Neuron (Lim et al., 2013), provide strong evidence
for a role of inherited recessive mutations in contributing to ASD.
We demonstrate the utility of our approach in identifying three
new ASD genes from a relatively small sample enriched for
recessive inheritance. We present three families that simplify
the identification of causative genes by narrowing genetic loci
to 1%–3% of the genome and allow identification of single muta-
tions that are rare and likely to be functional. These analyses
demonstrate a strategy for dissection of an otherwise highly
heterogeneous disorder. We present additional evidence that
biallelic mutations occur in other smaller families, as well as in
European American families from the Simons Simplex Collec-
tion. As high-quality whole-exome sequencing data from addi-
tional cohorts becomes available, it will be valuable to quantify
the prevalence of these biallelic mutations in ASD in general. A
common theme of many of the mutations identified in this cohort
is hypomorphic mutations that partially impair gene function,
though one or two null mutations are also identified.(B) Mapping to a locus on chromosome 6. Genome-wide linkage plot (top) and m
A homozygousmissense mutation in the AU-3500 family disrupts a conserved tryp
for import of PTS2-containing proteins into the peroxisome (D), and an establish
(E) PEX7 W75C and S25F, a previously characterized mutation from a patient wit
assay. In fibroblasts from patients with RCDP, PTS2-tagged mCherry accumulat
wild-type PEX7 cDNA causes PTS2-mCherry to redistribute to small puncta, ind
PEX7 W75C or S25F does not restore complete import, with a minority of cells s
mediated by ASD-associated PEX7 alleles, scored by visual assay. Error bars re
(F) Immunoblotting of whole cell lysates illustrates deficient maturation of PTS2
alleles. AGPS, PhyH, and thiolase are imported into the peroxisome and undergo
tubulin, loading control. Quantification of processing defects by densitometry ofThe finding of partially disabling mutations in AMT and PEX7
suggests that mild forms of neurometabolic conditions may
present with autistic symptoms, although such very mild muta-
tions may be quite rare, especially in nonconsanguineous popu-
lations. Although several neurometabolic disorders have been
associated with autistic symptoms (Zecavati and Spence,
2009; Novarino et al., 2012), milder forms of other metabolic
conditions may also be potentially missed by current newborn
or biochemical screening tests, which have limits to their sensi-
tivity (Watson et al., 2006). In analogous fashion, the rare biallelic
variants we identified in other syndromic neurodevelopmental
genes (VPS13B/COH1, SYNE1, MECP2, POMGNT1) also
seem to represent mutations in genes in which complete
knockout causes more severe syndromes, but which present
with milder ASD phenotypes when partially inactivated. Exome
sequencing will likely improve our ability to recognize these
difficult-to-diagnose cases. Metabolic conditions are especially
critical to identify since for some neurometabolic conditions,
interventions may be available.
In this study, we focused on identifying rare, deleterious,
penetrant variants that are causative of ASD in the families in
question. Our data does not rule out contributions of common
variation to ASD in other cases. While common variants are
under less selective pressure than rare variants and are more
likely to be benign, the functional impact of most common
variants is poorly understood. Some might be expected to lie
in autism gene pathways, impact biochemical function, and
modify disease risk. For example, a common deletion in TMLHE,
encoding the first enzyme in carnitine biosynthesis, has been
recently implicated as a risk factor for autism (Celestino-Soper
et al., 2012).
Genes implicated in this study include ones known to regulate
or be regulated by synaptic activity (MECP2, SYNE1) but also
genes not traditionally thought of as having synaptic roles
(AMT, PEX7, VPS13B/COH1). This could reflect an important
role for nonsynaptic genes and suggest the involvement of
hitherto unexpected pathways in ASDs. Alternatively, given the
strength of genetic evidence implicating genes of the synapse
as causative in ASDs, AMT, PEX7, and VPS13B/COH1 may
have involvement in synaptic pathways that have yet to be
characterized. AMT for example, regulates turnover of glycine,
a crucial inhibitory neurotransmitter (Baer, 2009; Keck and
White, 2009). PEX7 regulates peroxisomal protein import, and
peroxisomes are abundant in dendrites (Kou et al., 2011). Finally,
VPS13B/COH1 has essential roles in vesicle trafficking through
the Golgi apparatus (Seifert et al., 2011). Hence, while nullaximum obtainable LOD score in the family across the interval (bottom).
tophan (p.W75C) (C) in the first WD40 repeat of PEX7, the receptor responsible
ed cause of rhizomelic chondrodysplasia punctata.
h mild RCDP and ASD, result in partial loss of function in a peroxisomal import
es in the cytoplasm due to lack of PEX7 transport activity (top). Transfection of
icative of restoration of peroxisomal import (bottom). Transfection of mutant
howing partial import (middle). Quantification of defects in peroxisomal import
present standard error (right).
-targeted proteins in a RCDP cell line transfected with ASD-associated PEX7
cleavage into a smaller, mature peptide. p, preprotein; m, mature protein; Beta-
transfected cell lysates (right).
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Figure 3. Identification of Mutations in SYNE1 in a Family with ASD
(A) AU-1600, a family with four children affected with ASD. Shaded symbols indicate affected individuals. WES was performed on samples from individuals
indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference allele; –, alternate allele).
(B) Mapping rules out themajority of the genome and points out to only two candidate loci, one on chromosome 6 and the other on chromosome 7. Genome-wide
linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).
(C) SYNE1 is a complex locus implicated in neuropsychiatric disease. SYNE1 encompasses multiple alternative transcripts (Known Genes, UCSC Genome
Browser), and mutations have been associated with a wide range of neurodevelopmental phenotypes. The location of the recessively inherited missense change
(legend continued on next page)
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Figure 4. Schematic of the Analytical Pipeline
Tiered strategy for examining the cohort of ASD families for inheritedmutations
in known disease genes. Whole-exome sequencing data were used to
systematically survey 70 genes (listed in Table S2) known to be associatedwith
autosomal recessive or X-linked neurodevelopmental illness and autistic
features. Variants were filtered based on rarity (MAF < 1%) in known databases
and our internal, population-matched data set (see Experimental Procedures
for details), and predicted functional effect on the protein. All candidate vari-
ants were validated by Sanger sequencing and were required to segregate
within the family. XL, X-linked; AR, autosomal recessive; MAF, minor allele
frequency; 1000G, 1000 Genomes Project; NHLBI EVS5000, NHLBI Exome
Sequencing Project. See also Figure S4.
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phic mutations may cause subtler defects primarily limited to
neurons.
Our data support the interpretation that biallelic mutations in
the proper setting can cause a spectrum of clinical phenotypes,
which at one extreme cause a Mendelian disorder, but at the
other extreme represent risk alleles for ASDs. In our multiplex
pedigrees, siblings who share homozygosity for the identical
biallelic mutation still can show a variety of phenotypes, ranging
from ASD to intellectual disability, and including epilepsy and/or
other features. This variable expressivity has parallels in known
associations of ASD with Mendelian genes like FMR1 or TSC2,in this study is denoted by the green star. Late truncation (open triangle) causes au
truncating mutations further upstream (closed triangles) cause autosomal recess
a putative bipolar disorder susceptibility locus (Sklar et al., 2011). A de novo miss
(D) The homozygous missense mutation p.L3206M disrupts a highly conserved r
(E) Human neuronal ChIPseq and RNaseq data demonstrate transcriptional com
antibodies to H3K4Me3 (active promoters) and H3K27Ac (enhancers) demons
upstream of the residue mutated in AU-1600 (p.L3206M) and corresponds to the
performed before (0h, 0 hr) and after (6h, 6 hr) depolarization with KCl. Depolar
compared to untreated neurons (also see Figure S3). The experiment was perfo
square represents a magnification of the region around BC039121. Sense (+, pin
See also Table S5.which are near fully penetrant for syndromic features of Fragile
X or Tuberous Sclerosis, respectively, but only partially penetrant
for ASD (Hagerman et al., 2010; Wiznitzer, 2004). Variability of
phenotype is also characteristic of recurrent ASD-associated
CNVs, such as 16p11.2, which has been linked not only to
ASD but also to schizophrenia, epilepsy, ADHD, and obesity
(McCarthy et al., 2009; Shinawi et al., 2010; Walters et al.,
2010; Weiss et al., 2008). The common theme of variability of
phenotype despite underlying shared genetic susceptibility
increasingly suggests that highly penetrant mutations associ-
ated strictly with ASD, and never with other conditions, may be
extremely rare or nonexistent.
Our data extend the observation that hypomorphic alleles can
commonly cause conditions that may be dramatically different
from null mutations in the same gene (Walsh and Engle, 2010).
Hypomorphic, biallelic mutations, combined with CNVs and
heterozygous stop mutations (Neale et al., 2012; O’Roak et al.,
2012; Sanders et al., 2012) which completely inactivate one of
two alleles, suggest that a common theme for ASD mutations
in general might be partial loss of gene function and/or dosage
sensitivity. In other words, ASD, and potentially other neuropsy-
chiatric conditions, may be united by incomplete loss of function
of specific synaptic genes. Such incomplete lossmight provide a
general model for the complex genetic architecture, and genetic
heterogeneity, of ASDs. In this respect, neuropsychiatric condi-
tions may increasingly come to be understood as much by their
allelic architecture as by the specific causative genes.
EXPERIMENTAL PROCEDURES
Human Studies
All human studies were reviewed and approved by the institutional review
board of the Boston Children’s Hospital, Beth Israel Deaconess Medical
Center, and local institutions.
Patient Recruitment
The families presented were collected by the Homozygosity Mapping Collab-
orative for Autism (HMCA) (Morrow et al., 2008), with referral centers in Turkey,
the Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Oman, Jordan,
and Pakistan. Inclusion criteria included a diagnosis of autism or ASD by
a neurologist, child psychiatrist, or psychologist and families with multiple
affected children and/or suspected consanguinity. See Supplemental Experi-
mental Procedures for further phenotyping details. Additional clinical informa-
tion on families described here is provided in Supplemental Text.
Genome-wide Linkage and Homozygosity Scans
Genome-wide SNP screens were performed at the Broad Institute and
Dana Farber Cancer Institute. Families were genotyped using Affymetrix
500K (NspI/Sty) or Affymetrix 6.0 microarrays. Linkage disequilibrium-basedtosomal recessive arthrogyroposismultiplex congenita (Attali et al., 2009), while
ive cerebellar ataxia (Gros-Louis et al., 2007). An intronic SNP (red square) is
ense change was previously reported in ASD (blue star) (O’Roak et al., 2011).
esidue.
plexity and activity-dependent regulation of the SYNE1 locus. ChIPseq with
trates at least four active promoters (P1-P4) for SYNE1. P3 lies immediately
active promoter site for BC039121. RNAseq of cultured human neurons was
ization induces upregulation of full-length SYNE1 and the BC039121 isoform
rmed on five biological replicates. Representative tracks are shown. The red
k) and antisense (–, blue) transcripts are indicated.
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Figure 5. Identification of a Mutation in VPS13B, the Cohen Syndrome Gene, in a Patient with ASD
(A) AU-21100, a family with one child affected with ASD. Shaded symbol indicates affected individual. The triangle represents amiscarriage. WESwas performed
on samples from individuals indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference
allele; –, alternate allele).
(B) Photographs of proband, demonstrating mild facial dysmorphisms consistent with Cohen syndrome: prominent nasal tip, protruding maxilla, and short
philtrum. For additional clinical details, see Supplemental Text.
(C) Head circumference for proband compared to published population normative data (reprinted with permission from Schienkiewitz et al., 2011). KiGGS: norms
from German Health Interview and Examination Survey for Children and Adolescents, 2003–2006. Prader: previously published Swiss growth curves from 1989.
See also Table S5.
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Inherited Causes of AutismSNP pruning was performed with PLINK, followed by filtering of loci homozy-
gous in all samples and those with Mendelian inheritance errors. Multipoint
LOD scores were calculated using MERLIN, assuming a recessive mode
of disease inheritance, full penetrance, and a disease allele frequency of
0.0001. Runs of homozygosity were calculated using custom Perl scripts,
allowing for no more than two consecutive heterozygous SNPs in a run and
three heterozygous calls in every ten consecutive SNPs. Intervals homozygous
for the same haplotype and shared by all affected individuals were used to
narrow the locus in each family. See Supplemental Experimental Procedures
for details.
Whole-Exome Sequencing and Data Analysis
DNA samples were sequenced at the Broad Institute. Whole blood DNA was
subject to exome capture (SureSelect v2, Agilent Technologies) and whole-
exome sequence (Illumina HiSeq) was obtained on a total of 277 affected
children and 409 parents, with a mean target coverage of 85.6% at R203
and a mean read depth of 1583. For this study, families harboring known
autism-associated CNVs were excluded (Supplemental Experimental Proce-
dures). Reads were aligned to NCBI human genome build v37 and variants
were called and annotated using GATK. ANNOVAR (Wang et al., 2010) and
custom pipelines. All reported variants were confirmed by Sanger sequencing.
See Supplemental Experimental Procedures for additional details.
SSC Exome Reanalysis
Exome data from 612 families from the Simons Simplex Collection were
obtained from dbGAP and NDAR. Raw sequence reads were aligned with
BWA and variants were called with Samtools and annotated as previously
described (Sanders et al., 2012).
Sanger Resequencing
See Supplemental Experimental Procedures for details.
Data Visualization
See Supplemental Experimental Procedures for details.
AMT Expression and Enzymatic Assays
Wild-type and mutant human AMT proteins with a C-terminal His6-tag were
expressed and purified as previously described (Okamura-Ikeda et al.,
2005). I308F, I308A, D198G, or D198A substitutions were introduced using
site-directed mutagenesis, and enzymatic activities were determined as previ-
ously described (Okamura-Ikeda et al., 2010).270 Neuron 77, 259–273, January 23, 2013 ª2013 Elsevier Inc.For heat stability studies, wild-type and mutant AMTs (about 0.5 mg/ml in
20 mM Tris-HCl [pH 7.5], 1 mM DTT, 20 mM (p-amidinophenyl) methanesul-
fonyl fluoride, and 10% glycerol) were incubated for 1, 2, and 3 hr at 37C
and 42C. After incubation, the solutions were centrifuged and the protein
concentrations in the supernatants were determined using Coomassie Plus
(Thermo Scientific, USA) with BSA as standard. The remaining protein con-
centrations in the supernatant were showed as a percent of the initial
concentrations.
PEX7 Peroxisomal Import Assays
A peroxisomal import marker was generated by fusing mCherry fluorescent
protein to the PTS2 signal located in the first 26 amino acids of rat 3-ke-
toacyl-CoA thiolase [P07871.2] (Tsukamoto et al., 1994). N-terminal c-myc
tagged variants of PEX7 (W75C and S25F) were engineered using PCR
based site-directed mutagenesis of the N-myc-PEX7 cDNA [NM_000288]
in pCDNA1. PEX7 and PTS2-mCherry were transiently transfected into
an immortalized RCDP1 fibroblast line with a PEX7 null genotype (p.L292X];
[S132X) and processed at 3 days for direct and indirect immunofluorescence
as previously reported (Braverman et al., 2002). Recovery of peroxisomal
import was assessed by blinded visual scoring of 100 cells each from 3 sepa-
rate transfections. Peroxisomal import was confirmed by colocalization of the
peroxisome membrane protein PEX14. Whole cell lysates from similarly trans-
fected fibroblasts were used for immunoblotting with antibodies to the endog-
enous PTS2 proteins thiolase, PhyH, and AGPS (Zhang et al., 2010). PEX7
protein expression was confirmed with a c-myc antibody (SC789, Santa
Cruz Biotechnology Inc., Santa Cruz, CA).
RNaseq of Human Neurons
Primary human neuronal cells were purchased from Sciencell (Carlsbad, CA).
For RNaseq experiments, neuronal cultures from three biological replicates
were grown for around two weeks (DIV13–16). At the final day in culture,
neurons in the experimental group were stimulated for 6 hr with 55 mM KCl
and were harvested along with the unstimulated control neurons using Trizol
(Invitrogen). Strand-specific and paired-end cDNA libraries were generated
using the PE RNaseq library kit (Illumina). RNaseq was performed using HiSeq
2000 at the Broad Institute. 76-bp RNaseq reads were aligned to the human
GRCh37/hg19 assembly using BWA. See Supplemental Experimental Proce-
dures for details. For quantification of SYNE1 expression in response to depo-
larization, for each biological replicate, expression levels (normalized reads per
bp) of individual exons were calculated, which allowed the calculation of the
average expression level over any isoform of SYNE1 comprising subsets of
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Inherited Causes of Autismthese exons. Then fold-change ratios (6 hr/unstimulated) of these levels were
calculated for each replicate and isoform, and finally each isoform’s mean and
standard error over the replicates’ fold changes.
ChIPseq of Human Neurons
The mini-ChIP assays were performed as previously described (Adli and Bern-
stein, 2011) on human neuronal cells that had been cultured for around two
weeks. Briefly, cells were cross-linked, lysed, and the fragmented chromatin
was then immunoprecipated with H3K27Ac (Abcam Cat# ab4728) and
H3K27me3 (Millipore Cat# 074490) antibodies. The ChIP DNA was recovered
and precipitated following standard procedures. The ChIP DNA libraries were
then constructed using ChIP-Seq DNA Sample Prep Kit (Illumina) and subse-
quently sequenced using HiSeq 2000 (Illumina) in Biopolymers facility at
Harvard Medical School. ChIPseq reads were aligned to the human genome
(GRCh37/hg19 assembly). See Supplemental Experimental Procedures for
details.
Data Access
Whole-exome sequence data is available online (The National Database for
Autism Research [NDAR] Collection ID: NDARCOL0001918).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, five tables, Supplemental
Experimental Procedures, and Supplemental Text and can be found with
this article online at http://dx.doi.org/10.1016/j.neuron.2012.11.002.
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